ArriVent BioPharma Inc AVBP
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-01-26 |
| Shares Out. | 46,570,000 |
| Website | arrivent.com/ ↗ |
| Phone | 12407806356 |
| Employees | 77 |
| Net Income | -$43.3M |
| Total Assets | $349.3M |
| Total Liabilities | $25.3M |
| Equity | $324.0M |
About ArriVent BioPharma Inc
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
ArriVent BioPharma Inc is a publicly traded company under the ticker symbol AVBP on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
19 analysts (2026-07-01)